Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...

Pfizer Inc. PFE and partner Arvinas Inc. ARVN shares rose Monday after the companies secured a key regulatory win, with the U ...

VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.

Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...

Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...

By Padmanabhan Ananthan May 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast ...

On launch, Veppanu will join Menarini/Stemline's Orserdu (elacestrant) and Eli Lilly's Inluriyo (imlunestrant), which were ...

The U.S. Food and Drug Administration (FDA) has approved a label change for Pfizer Inc.'s (NYSE: PFE) Depo-Provera contraceptive injection, adding a warning about the risk of meningioma, a type of ...

The U.S. FDA on Tuesday granted traditional approval for a first-line combination regimen involving Braftovi, an oral cancer drug developed by Pfizer (PFE) in partnership with companies such as ...

Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, ...